Equity research, Immunovia: Announced rights issue and pause of coverage

2026-09-29 09:52:00

Yesterday, on 28 September, Immunovia announced a partly guaranteed rights issue of units of about SEK 63m initially, with a subscription period from 9 November to 23 November 2026.

As Carlsquare is an advisor on this transaction, our research coverage of Immunovia is paused until the issue is completed.
Consequently, our previous estimates and valuations for Immunovia no longer apply and will be updated when coverage resumes.

About Carlsquare

Carlsquare is a global research firm and financial advisor, focusing on M&A, Equity
Research and Growth Equity. Carlsquare has 150 employees with deep sector knowledge in all 11
GICS sectors. The senior equity research team has extensive experience about the stock
environment and several business sectors. The team produces company research reports,
independent valuations and trading notes. The group have offices in Canada, Denmark, France, Germany, Poland, Sweden, United Kingdom and United States. Read more